
    
      This study is a single site, non-randomized, prospective, phase IV trial.

      Composed of 4 patient groups:

        1. Oligometastases (1-3) with aggregate tumor diameter < 6 cm

        2. Metastases from neuroendocrine tumors with functional endocrine syndromes

        3. Unresectable hepatocellular carcinoma (HCC)

        4. Unresectable intrahepatic cholangiocarcinoma (IHCC) Data collected will include patient
           demographics, pathology data, tumor stage, SBRT dose fractionation scheme, dose received
           by adjacent critical normal tissues, tumor recurrence data, and acute and late
           toxicities. Follow up data will be collected during the patient's standard office
           visits. The anticipated duration of this study is 5 years.
    
  